Company intelligence / Profile preview

Avicenna Oncology

Basel, Switzerland

Ownership: Private
Employees: ~10
Development stage: Other

Overview

CLR-2000, a phospholipid drug conjugate for solid tumors developed in collaboration with Cellectar Biosciences, is in preclinical stage

Therapeutic areas: Oncology
Modalities: Small moleculePhospholipid drug conjugate
Industry: Biotech

Partnerships

Cellectar Biosciences: Collaboration to develop phospholipid drug conjugates combining Cellectar's phospholipid ether delivery platform with Avicenna's novel cytotoxic payloads for solid tumors (2017)

Beyond the preview

Go deeper on Avicenna Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avicenna Oncology.

Explore the full profile